Immunoprecipitation and opsonic cross-reaction between type-14 pneumococcus and group-B streptococcus type III.
Antisera directed against type-14 pneumococcus was opsonic for several strains of type-III group-B streptococcus. Furthermore, the polysaccharide antigen in the polyvalent pneumococcal vaccine reacted to form precipitation lines with antisera directed against type-14 pneumococcus and group-B streptococcus type III Immunisation with currently available pneumococcal vaccine may provide opsonic antibody against group-B streptococci and provide a method of preventing neonatal group-B streptococcal infections.
D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000942:Antigens, Bacterial / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology; D001770:Blood Bactericidal Activity; D003429:Cross Reactions; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000276:immunology; D007153:Immunologic Deficiency Syndromes / Q000517:prevention & control; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000517:prevention & control; D009504:Neutrophils / Q000276:immunology; D009895:Opsonin Proteins / Q000276:immunology*; D011008:Pneumococcal Infections / Q000517:prevention & control; D011233:Precipitin Tests; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D011817:Rabbits; D013290:Streptococcal Infections / Q000517:prevention & control; D013292:Streptococcus agalactiae / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D007106:Immune Sera; D009895:Opsonin Proteins